P/E ratio for Heron Therapeutics (HRTX)
P/E ratio as of April 2024 (TTM): -2.09
According to Heron Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.09402. At the end of 2022 the company had a P/E ratio of -1.45.
P/E ratio history for Heron Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.45 | -64.39% |
| 2021 | -4.06 | -52.08% |
| 2020 | -8.47 | -9.91% |
| 2019 | -9.40 | -10.49% |
| 2018 | -10.5 | 112.94% |
| 2017 | -4.93 | 71.3% |
| 2016 | -2.88 | -68.3% |
| 2015 | -9.08 | 160.89% |
| 2014 | -3.48 | 33.44% |
| 2013 | -2.61 | -57.31% |
| 2012 | -6.11 | 248.86% |
| 2011 | -1.75 | -29.93% |
| 2010 | -2.50 | -36.51% |
| 2009 | -3.94 | 603.13% |
| 2008 | -0.5600 | 55.6% |
| 2007 | -0.3599 | -76.09% |
| 2006 | -1.51 | -67.53% |
| 2005 | -4.64 | 18.02% |
| 2004 | -3.93 | -66.33% |
| 2003 | -11.7 | 296.67% |
| 2002 | -2.94 | -86.34% |
| 2001 | -21.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 SurModics SRDX | -15.9 | 657.42% | 🇺🇸 USA |
 Pacira Biosciences
PCRX | 188 | -9,081.34% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 44.9 | -2,246.54% | 🇺🇸 USA |
 Alkermes ALKS | 19.0 | -1,006.61% | 🇮🇪 Ireland |
 Nektar Therapeutics
NKTR | -0.8098 | -61.33% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.